Status:

UNKNOWN

Medical and Economic Evaluation for Intermediate-risk Prostate Cancer

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Prostate Cancer

Eligibility:

MALE

18-80 years

Phase:

NA

Brief Summary

The aim of the present phase III study is two-folded: 1) to show a superiority of external beam radiotherapy combined with a brachytherapy boost versus exclusive external beam radiotherapy and 2) to e...

Eligibility Criteria

Inclusion

  • age between 18 and 80 years;
  • life expectancy of greater than 10 years;
  • prostate adenocarcinoma histologically proven;
  • prostate cancer has to be of intermediate-risk based on at least one of the three following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7 and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status ECOG 0-2.
  • the patient has to be the beneficiary of the social security system (order n° 2006-477 from April 26th 2006);
  • the signed consent form.

Exclusion

  • PSA level \> 20;
  • Gleason \> 7;
  • clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A won't be an exclusion criterion);
  • prostate volume \> 60 cc;
  • pelvic lymph nodes involvement at dissection or imaging (ADP \> 1.5 cm);
  • concurrent hormone therapy;
  • the presence of distant metastasis (M1);
  • history of abdominal or pelvic irradiation;
  • history of prostate resection in the previous 6 months and/or not allowing the implantation of markers;
  • history of uncontrolled cancer and/or treated since less than 5 years (excepting the basal-cell carcinoma);
  • urinary discomfort with an IPSS (International Prostate Symptom Score) \> 15 (without alpha-blocking);
  • inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease;
  • other undergoing study that may interfere with the present study;
  • patient under legal protection measure.

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2021

Estimated Enrollment :

298 Patients enrolled

Trial Details

Trial ID

NCT02271659

Start Date

June 1 2013

End Date

June 1 2021

Last Update

September 13 2016

Active Locations (29)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (29 locations)

1

Clinique Claude Bernard

Albi, France, 81000

2

CHU Jean MINJOZ

Besançon, France, 25030

3

Clinique Tivoli

Bordeaux, France, 33000

4

Institut Bergonie

Bordeaux, France, 33076